Infliximab 사용한 후 발생한 결핵성 흉막염
Occurrence of tuberculous pleurisy associated with infliximab therapy
3
조회
0
다운로드
2
인용
0
참고문헌
초록
Infliximab (Remicaid)은 기존의 류마티스 약제로는 좋은 효과를 보지 못했던 강직성 척추염 환자에서 사용할 수 있는 약물이다. 이 약물은 강직성 척추염의 진행을 막는데 효과적인 반면 결핵을 일으키는 부작용이 있다. 외국의 경우 이런 부작용은 많이 보고 되어 있지만, 아직 국내에서는 보고가 없다. 본 저자들은 강직성 척추염 환자에서 infiximab을 사용한 뒤 결핵성 흉막염이 합병되는 경우를 경험하였기에 문헌고찰과 함께 보고하는 바이다.
Abstract
Infliximab is a chimeric antibody against tumor necrosis factor-α and it can be used in the treatment of ankylosing spondylitis. Tumor necorosis factor-α is a potent proinflammatory cytokine and plays a key role in the host response against tuberculosis. Infliximab is known to be effective on active ankylosing spondylitis but it can also cause reactivation of latent tuberculosis. Physicians should screen patients for latent tuberculous infection or disease before prescribing the drug. We experienced a case of tuberculous pleurisy after taking infliximab in a patient suffering from ankylosing spondylitis. We present the case with a review of literature.
참고문헌 (13)
- "Harrison's priciples of internal medicine", pp.1805~1830 (2001), Mc Graw-Hill
- "Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study", 41, pp.1280~1285 (2002)
- "The treatment of ankyl-osing spondyltitis", 2, pp.159~165 (2003)
- "Anti-tumor necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management", 3, pp.148~155 (2003)
- "Tuberculosis associated with infliximab, a tumor necrosis f actor-neutralizing agent", 345, pp.1098~1104 (2001)
- "Tumor necrosis factor-inhibitors and the reactivation of latent tuberculosis infection", 168, pp.1153~1156 (2003)
- "Recommendations about the prevention and management of tuberculosis in patients taking infliximab", 69, pp.170~172 (2002)
- "Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid", 30, pp.1657~1658 (2003)
- "Immunological basis for the use of TNF -alpha blocking agents in ankylosing spondylitis and immunological changes during treatment", 20, pp.34~37 (2002)
- "Pathology", pp.423~427 (1999), Lippincott-Raven
- "Cytokine pathways and joint inflammation in rheumatoid arthritis", 344, pp.907~916 (2001)
- "Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial", 359, pp.1187~1193 (2002)
- "Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk", 48, pp.2122~2127 (2003)